XSTOMOB
Market cap44mUSD
Dec 23, Last price
10.50SEK
1D
-0.76%
1Q
4.27%
Jan 2017
-96.76%
IPO
-93.46%
Name
Moberg Pharma AB (publ)
Chart & Performance
P/E
—
P/S
—
EPS
—
Div Yield, %
0.00%
Shrs. gr., 5y
50.51%
Rev. gr., 5y
-77.18%
Revenues
0k
-100.00%
Net income
-21m
L+34.26%
CFO
-33m
L+97.16%
Dividend
Nov 04, 20194.65 SEK/sh
Earnings
Feb 11, 2025
Profile
Moberg Pharma AB (publ), a pharmaceutical company, develops and commercializes medical products in Europe, the United States, and internationally. It develops MOB-015, which has completed Phase III clinical trial for the treatment of nail fungus. The company was formerly known as Moberg Derma AB (publ) and changed its name to Moberg Pharma AB (publ) in May 2013. Moberg Pharma AB (publ) was incorporated in 2006 and is headquartered in Bromma, Sweden.
Valuation
Title SEK in thousands, except ratios and share amounts | FY | FY | FY | FY | FY | FY | FY | FY | FY |
|---|---|---|---|---|---|---|---|---|---|
| 2023‑12 | 2022‑12 | 2021‑12 | 2020‑12 | 2018‑12 | 2017‑12 | 2016‑12 | 2015‑12 | 2014‑12 | |
| Income | |||||||||
Revenues | 207 | ||||||||
Cost of revenue | 29,340 | 44,887 | 42,979 | ||||||
Unusual Expense (Income) | |||||||||
NOPBT | (29,340) | (44,680) | (42,979) | ||||||
NOPBT Margin | |||||||||
Operating Taxes | (4,327) | (3,802) | (3,748) | ||||||
Tax Rate | |||||||||
NOPAT | (25,013) | (40,878) | (39,231) | ||||||
Net income | (21,093) 34.26% | (15,710) -3.16% | (16,222) -14.74% | ||||||
Dividends | |||||||||
Dividend yield | |||||||||
Proceeds from repurchase of equity | 94,751 | 109,682 | 133,438 | ||||||
BB yield | |||||||||
| Debt | |||||||||
Debt current | 1,270 | 2,117 | 2,696 | ||||||
Long-term debt | 8,204 | 10,093 | 5,166 | ||||||
Deferred revenue | |||||||||
Other long-term liabilities | 65 | 65 | |||||||
Net debt | (51,081) | (118,624) | (98,612) | ||||||
| Cash flow | |||||||||
Cash from operating activities | (33,205) | (16,842) | (15,296) | ||||||
CAPEX | (124,116) | (68,072) | (31,309) | ||||||
Cash from investing activities | (124,116) | (68,072) | (41,308) | ||||||
Cash from financing activities | 92,326 | 107,809 | 129,974 | ||||||
FCF | (23,971) | (42,343) | (36,647) | ||||||
| Balance | |||||||||
Cash | 60,555 | 124,850 | 101,955 | ||||||
Long term investments | 5,984 | 4,519 | |||||||
Excess cash | 60,555 | 130,824 | 106,474 | ||||||
Stockholders' equity | (310,572) | (307,613) | (297,325) | ||||||
Invested Capital | 926,034 | 847,182 | 735,127 | ||||||
ROIC | |||||||||
ROCE | |||||||||
| EV | |||||||||
Common stock shares outstanding | 15,872 | 11,381 | 6,856 | ||||||
Price | |||||||||
Market cap | |||||||||
EV | |||||||||
EBITDA | (27,241) | (42,098) | (40,395) | ||||||
EV/EBITDA | |||||||||
Interest | 260 | 71 | 129 | ||||||
Interest/NOPBT | |||||||||